




PHARMACEUTICAL 2018

Theriva Biologics Inc.
Rank 249 of 342





PHARMACEUTICAL 2018

Theriva Biologics Inc.
Rank 249 of 342

The relative strengths and weaknesses of Theriva Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theriva Biologics Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Theriva Biologics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 70% points.

The company's Economic Capital Ratio, given in the ranking table, is -4.3%, being 50% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	17,943
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,793
Liabilities, Non-Current	0
Other Assets	23
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	402
Other Net Income	10,759
Other Revenues	0
Property and Equipment	872
Research and Development	18,784
Selling, General and Administrative Expense	7,467

Output Variable	Value in 1000 USD
Assets	18,838
Liabilities	10,195
Expenses	26,251
Revenues	0
Stockholders Equity	8,643
Net Income	-15,492
Comprehensive Net Income	-15,492
Economic Capital Ratio	-4.3%